ArticleJournal of neuro-oncology2016
Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience.
Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 75 citations in OpenAlex.
- Long term outcomes and predictors of recurrence in central neurocytomas: a 35-year multi-institutional experience.Journal of neuro-oncology · 2026Article
- Central neurocytomas: Decision-making process of postoperative treatment. Lesson learned.Neurosurgical review · 2026Article
- Improved tumor control with adjuvant radiotherapy in patients with central neurocytoma: a multicenter study.Journal of neuro-oncology · 2026Article
- Atypical central neurocytoma with anaplastic histological features in the lateral ventricle of a 37-year-old man.Free neuropathology · 2026Article
- Outcome-associated factors in a molecularly defined cohort of central neurocytoma.Acta neuropathologica · 2025Article
- The clinical spectrum of central neurocytomas ranges from benign to leptomeningeal disseminating disease: a single institutional surgical series of 33 patients.Frontiers in surgery · 2025Article
- Article
- Risk factors for early intraventricular hemorrhagic complications following lateral ventricular tumor surgery.Neurosurgical review · 2024Article
- Molecular and clinical characterization of atypical central neurocytomas: implications for diagnosis and treatment strategies.Discover oncology · 2024Article
- Article
- Whole-exome sequencing reveals genetic variants that may play a role in neurocytomas.Journal of neuro-oncology · 2024Article
- Central neurocytomas in children: Clinicopathologic features and long-term surgical outcomes.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023Article
- Comparison of surgery with or without adjuvant radiotherapy in treating central neurocytoma: a single-center retrospective real-world study.Journal of neuro-oncology · 2022Article
- Malignant transformation of central neurocytoma with dissemination 17 years after initial treatment: illustrative case.Journal of neurosurgery. Case lessons · 2022Article
- Clinical prognostic factors for central neurocytoma and subgroup analysis of different treatment measures: A SEER database-based retrospective analysis from 2003 to 2019.Frontiers in oncology · 2022Article
- Clinical Outcomes and Prognostic Analysis of 101 Patients of Central Neurocytoma: A 10-Year Treatment Experience at a Single Institution.Frontiers in oncology · 2022Article
- Central Neurocytoma with Hemorrhagic Presentation Case Report and Review of the Literature.Case reports in surgery · 2022Article
- The last decade's experience of management of central neurocytomas: Treatment strategies and new options.Surgical neurology international · 2021Article
- Intraventricular neuroepithelial tumors: surgical outcome, technical considerations and review of literature.BMC cancer · 2020Observational
- Atypical central neurocytoma with aggressive features in a child.BMJ case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Funding
Abstract
Central neurocytomas are uncommon intraventricular neoplasms whose optimal management remains controversial due to their rarity. We assessed outcomes for a historical cohort of neurocytoma patients and evaluated effects of tumor atypia, size, resection extent, and adjuvant radiotherapy. Progression-free survival (PFS) was measured by Kaplan-Meier and Cox proportional hazards methods. A total of 28 patients (15 males, 13 females) were treated between 1995 and 2014, with a median age at diagnosis of 26 years (range 5-61). Median follow-up was 62.2 months and 3 patients were lost to follow-up postoperatively. Thirteen patients experienced recurrent/progressive disease and 2-year PFS was 75% (95% CI 53-88%). Two-year PFS was 48% for MIB-1 labeling >4% versus 90% for ≤4% (HR 5.4, CI 2.2-27.8, p = 0.0026). Nine patients (32%) had gross total resections (GTR) and 19 (68%) had subtotal resections (STR). PFS for >80% resection was 83 versus 67% for ≤80% resection (HR 0.67, CI 0.23-2.0, p = 0.47). Three STR patients (16%) received adjuvant radiation which significantly improved overall PFS (p = 0.049). Estimated 5-year PFS was 67% for STR with radiotherapy versus 53% for STR without radiotherapy. Salvage therapy regimens were diverse and resulted in stable disease for 54% of patients and additional progression for 38 %. Two patients with neuropathology-confirmed atypical neurocytomas died at 4.3 and 113.4 months after initial surgery. For central neurocytomas, MIB-1 labeling index >4% is predictive of poorer outcome and our data suggest that adjuvant radiotherapy after STR may improve PFS. Most patients requiring salvage therapy will be stabilized and multiple modalities can be effectively utilized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.